Identifier to cite or link to this item:

https://hdl.handle.net/20.500.13003/20643

Real-world biologics response and super-response in the International Severe Asthma Registry cohort

Loading...
Thumbnail Image
Identifiers

Authors

Denton, Eve
Hew, Mark
Peters, Matthew J
Upham, John W
Bulathsinhala, Lakmini
Tran, Trung N
Martin, Neil
Bergeron, Celine
Al-Ahmad, Mona
Altraja, Alan

Advisors

Metrics
Google Scholar
Share
Export

Date of defense

Publication date

2024-06-22

Document type

research article

Citation

Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024 Jun 22.

Volume Title

Research Projects

Organizational Units

Abstract

Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma. Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super-response criteria were: FEV1 increase by ≥500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day. 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria. Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria.

Description

Research data

Referenced by

It is version of

It is versioned by

Keywords

MeSH

DeCS

This item appears in following Docusalut collections

Atribución-NoComercial 4.0 Internacional

La licencia de este ítem se describe como Atribución-NoComercial 4.0 Internacional